ReviewFrontiers in immunology2019
Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 98 citations in OpenAlex.
- Complete Blood Count-Derived Inflammatory Markers in Pediatric Lower Respiratory Tract Infection: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy.CPT: pharmacometrics & systems pharmacology · 2026Article
- Screening of key host targets and mechanistic assessment of berberine modulation of host responses to respiratory syncytial virus.The Journal of international medical research · 2026Article
- A Retrospective Unicenter Study of Clinical and Inflammatory Features in Hospitalized Adults with Respiratory Syncytial Virus Infection Across Two Epidemic Waves in Catalonia, Spain.Journal of clinical medicine · 2026Article
- Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2-<18 Year Olds.Vaccines · 2026Article
- Characteristics and outcomes of hospitalized adult patients with respiratory syncytial virus infection in different age groups.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Identification of Virus-Host Interactions.Advances in experimental medicine and biology · 2026Review
- Immune-endothelial-coagulation crosstalk as a driver of multi-organ dysfunction in severe viral pneumonia.Frontiers in immunology · 2026Review
- Review
- Single cell sequencing analysis of respiratory syncytial virus-infected pediatric and adult human nose organoids reveals age differences, proliferative diversity and identifies novel cellular tropism.The Journal of infection · 2025Article
- Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom.International journal of technology assessment in health care · 2025Article
- Exploring CCND1 as a Key Target ofCurrent issues in molecular biology · 2025Article
- RSV: an overview of infection in adults.Pneumonia (Nathan Qld.) · 2025Review
- Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.Asian biomedicine : research, reviews and news · 2025Review
- Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention.Journal of clinical medicine · 2025Review
- Clinical features and survival analysis of adult patients with severe lower respiratory tract infection positive for respiratory syncytial virus.BMC pulmonary medicine · 2025Article
- Seasonal Incidence of Medically Attended Respiratory Syncytial Virus Infection From 2015 to 2019 in a Cohort of Adults With High-risk Conditions.Open forum infectious diseases · 2025Article
- Circulation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System.Microorganisms · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the most prevalent viral etiological agent of acute respiratory tract infection. Although RSV affects people of all ages, the disease is more severe in infants and causes significant morbidity and hospitalization in young children and in the elderly. Host factors, including an immature immune system in infants, low lymphocyte levels in patients under 5 years old, and low levels of RSV-specific neutralizing antibodies in the blood of adults over 65 years of age, can explain the high susceptibility to RSV infection in these populations. Other host factors that correlate with severe RSV disease include high concentrations of proinflammatory cytokines such as interleukins (IL)-6, IL-8, tumor necrosis factor (TNF)-α, and thymic stromal lymphopoitein (TSLP), which are produced in the respiratory tract of RSV-infected individuals, accompanied by a strong neutrophil response. In addition, data from studies of RSV infections in humans and in animal models revealed that this virus suppresses adaptive immune responses that could eliminate it from the respiratory tract. Here, we examine host factors that contribute to RSV pathogenesis based on an exhaustive review of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.